Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 117

1.

Influence of the vaginal microbiota on toxic shock syndrome toxin 1 production by Staphylococcus aureus.

MacPhee RA, Miller WL, Gloor GB, McCormick JK, Hammond JA, Burton JP, Reid G.

Appl Environ Microbiol. 2013 Mar;79(6):1835-42. doi: 10.1128/AEM.02908-12. Epub 2013 Jan 11.

2.

Persistence survey of toxic shock syndrome toxin-1 producing Staphylococcus aureus and serum antibodies to this superantigen in five groups of menstruating women.

Parsonnet J, Hansmann MA, Seymour JL, Delaney ML, Dubois AM, Modern PA, Jones MB, Wild JE, Onderdonk AB.

BMC Infect Dis. 2010 Aug 23;10:249. doi: 10.1186/1471-2334-10-249.

3.

Staphylococcus aureus toxic shock syndrome toxin-1 (TSST-1) production and Lactobacillus species growth in a defined medium simulating vaginal secretions.

Stingley RL, Liu H, Mullis LB, Elkins CA, Hart ME.

J Microbiol Methods. 2014 Nov;106:57-66. doi: 10.1016/j.mimet.2014.08.002. Epub 2014 Aug 16.

PMID:
25135489
4.
6.

Prevalence of toxic shock syndrome toxin 1 (TSST-1)-producing strains of Staphylococcus aureus and antibody to TSST-1 among healthy Japanese women.

Parsonnet J, Goering RV, Hansmann MA, Jones MB, Ohtagaki K, Davis CC, Totsuka K.

J Clin Microbiol. 2008 Aug;46(8):2731-8. doi: 10.1128/JCM.00228-08. Epub 2008 Jun 11.

7.

A toroid model for in vitro investigations of toxic shock syndrome toxin-1 production.

Flood JA, Tripp TJ, Davis CC, Hill DR, Schlievert PM.

J Microbiol Methods. 2004 May;57(2):283-8.

PMID:
15063069
10.

Staphylococcus aureus isolates from patients with nonmenstrual toxic shock syndrome. Evidence for additional toxins.

Garbe PL, Arko RJ, Reingold AL, Graves LM, Hayes PS, Hightower AW, Chandler FW, Broome CV.

JAMA. 1985 May 3;253(17):2538-42.

PMID:
3981783
11.

Prevalence of toxic shock syndrome toxin 1-producing Staphylococcus aureus and the presence of antibodies to this superantigen in menstruating women.

Parsonnet J, Hansmann MA, Delaney ML, Modern PA, Dubois AM, Wieland-Alter W, Wissemann KW, Wild JE, Jones MB, Seymour JL, Onderdonk AB.

J Clin Microbiol. 2005 Sep;43(9):4628-34.

12.

Surfactants, aromatic and isoprenoid compounds, and fatty acid biosynthesis inhibitors suppress Staphylococcus aureus production of toxic shock syndrome toxin 1.

McNamara PJ, Syverson RE, Milligan-Myhre K, Frolova O, Schroeder S, Kidder J, Hoang T, Proctor RA.

Antimicrob Agents Chemother. 2009 May;53(5):1898-906. doi: 10.1128/AAC.01293-08. Epub 2009 Feb 17.

13.
14.

Lactobacillus reuteri-produced cyclic dipeptides quench agr-mediated expression of toxic shock syndrome toxin-1 in staphylococci.

Li J, Wang W, Xu SX, Magarvey NA, McCormick JK.

Proc Natl Acad Sci U S A. 2011 Feb 22;108(8):3360-5. doi: 10.1073/pnas.1017431108. Epub 2011 Jan 31.

15.

Staphylococcus aureus producing toxic shock syndrome toxin 1 (TSST-1) in clinical specimens and vaginal swabs in Mannheim, West Germany.

Dickgiesser N, Brombacher A.

Zentralbl Bakteriol Mikrobiol Hyg A. 1987 Jul;265(3-4):323-9.

PMID:
3314262
16.

The innate immune system is activated by stimulation of vaginal epithelial cells with Staphylococcus aureus and toxic shock syndrome toxin 1.

Peterson ML, Ault K, Kremer MJ, Klingelhutz AJ, Davis CC, Squier CA, Schlievert PM.

Infect Immun. 2005 Apr;73(4):2164-74.

17.

On the pathogenesis of toxic shock syndrome.

Kass EH, Parsonnet J.

Rev Infect Dis. 1987 Sep-Oct;9 Suppl 5:S482-9. Review.

PMID:
3317745
18.
20.

[Correlation in Staphylococcus aureus infections between toxic shock syndrome toxin-1 production and clinical feature].

Kiyota H, Ohishi Y, Onodera S, Miki K, Ueda M.

Kansenshogaku Zasshi. 1998 Jun;72(6):593-8. Japanese.

PMID:
9695469
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk